Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up
T Huang, Y Liu, Y Li, Y Liao, Q Shou, M Zheng, X Liao… - Vaccine, 2018 - Elsevier
Background This was an extension study of a randomized, double-blind, placebo-controlled
immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV)(HPV 6 …
immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV)(HPV 6 …
Post-marketing safety surveillance study of a 9-valent human papillomavirus vaccine in individuals aged 16–26 years in Chongqing, China
Y Zhang, JW Xu, Y Liu, W Qiu, PN Bai… - Human Vaccines & …, 2023 - Taylor & Francis
The safety of human papillomavirus (HPV) vaccines, one of the major challenges to public
vaccination, has been controversial. This study assessed the adverse reactions of 9-valent …
vaccination, has been controversial. This study assessed the adverse reactions of 9-valent …
The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age
C Zhao, Y Zhao, J Li, M Li, Y Su, X Mi… - Human Vaccines & …, 2022 - Taylor & Francis
The quadrivalent human papillomavirus (4vHPV) vaccine has shown confirmative
effectiveness in preventing HPV-related diseases among women and men around the …
effectiveness in preventing HPV-related diseases among women and men around the …
[HTML][HTML] Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial
DG Ferris, DR Brown, AR Giuliano, E Myers… - Papillomavirus …, 2020 - Elsevier
Objectives The natural history of human papillomavirus (HPV) infection has been studied
extensively in young women; this study investigated HPV infection in adult women. Methods …
extensively in young women; this study investigated HPV infection in adult women. Methods …
Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years)
F Guo, JM Hirth, AB Berenson - Human Vaccines & …, 2015 - Taylor & Francis
There is some concern about the effectiveness of the HPV vaccine among young adult
women due to the risk of prior HPV infection. This study used National Health and Nutrition …
women due to the risk of prior HPV infection. This study used National Health and Nutrition …
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised …
N Muñoz, R Manalastas, P Pitisuttithum, D Tresukosol… - The Lancet, 2009 - thelancet.com
Background Although the peak incidence of human papillomavirus (HPV) infection occurs in
most populations within 5–10 years of first sexual experience, all women remain at risk for …
most populations within 5–10 years of first sexual experience, all women remain at risk for …
Human papillomavirus vaccine effectiveness against HPV infection: evaluation of one, two, and three doses
LE Markowitz, AL Naleway, NP Klein… - The Journal of …, 2020 - academic.oup.com
Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …
Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages
Q Chen, H Zhao, X Yao, Z Lin, J Li, B Lin, R Wang… - Vaccine, 2020 - Elsevier
Background The safety and efficacy of a recently licensed Escherichia coli (E. coli)-produced
bivalent HPV vaccine have been shown. Specific antibody levels are important indicators to …
bivalent HPV vaccine have been shown. Specific antibody levels are important indicators to …
Prevalence and genotype distribution of human papillomavirus infection among women aged 30–65 years in Xi'an, China: a population-based study of 14,655 women
X Han, G Song, Y Li, Z Dong, X Yan… - Human Vaccines & …, 2021 - Taylor & Francis
Cervical cancer is the fourth most common cancer among women worldwide in terms of both
incidence and mortality. Persistent infection with high-risk human papillomavirus (HPV) has …
incidence and mortality. Persistent infection with high-risk human papillomavirus (HPV) has …
Efficacy, immunogenicity and safety of the AS04‐HPV‐16/18 vaccine in Chinese women aged 18‐25 years: End‐of‐study results from a phase II/III, randomised …
FC Zhu, SY Hu, Y Hong, YM Hu, X Zhang… - Cancer …, 2019 - Wiley Online Library
Background Cervical cancer is a major public health concern in China. We report the end‐of‐
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …
study results of a phase II/III trial to assess the efficacy, immunogenicity, and safety of the …